Billionaire investor David Einhorn hedge fund, Greenlight Capital, had a remarkable year in 2022, posting returns of 36.6% despite the S&P 500 losing 19%. Einhorn’s investment strategy proved effective in 2022, and the fund is optimistic that it will continue to deliver attractive returns in the future.
Greenlight Capital’s Investment Strategy
Einhorn’s investment strategy is based on value investing principles, which involve identifying undervalued companies and investing in them for the long term. The fund has a concentrated portfolio of 25-30 positions, with a focus on technology, healthcare, and consumer discretionary sectors.
David Einhorn Moves on Global Payments (GPN)
Global Payments (GPN) is a fintech company that provides payment technology and software solutions to businesses worldwide. Einhorn increased his stake in GPN by 74% during Q4 2022, indicating his confidence in the company’s growth prospects.
Analysts are optimistic about GPN, with a consensus rating of Moderate Buy and an average price target of $139.47, suggesting a 23% potential upside. GPN’s strong fundamentals, including a growing customer base, innovative product offerings, and solid financials, make it an attractive investment opportunity.

David Einhorn Moves on Tenet Healthcare (THC)
Tenet Healthcare (THC) is a healthcare services provider that manages hospitals and outpatient centers. During Q4 2022, Einhorn initiated a new position in THC, indicating his interest in the healthcare sector.
THC exceeded expectations for both revenue and earnings in Q4 2022, indicating its strong fundamentals. However, the company’s outlook for Q1 2023 was underwhelming, which resulted in mixed views from analysts.
Analysts have a consensus rating of Hold and an average price target of $41.17 for THC, suggesting a potential upside of 9%. THC’s strengths include a diverse portfolio of healthcare services and a strong balance sheet, making it a viable investment opportunity.

Conclusion
In conclusion, Greenlight Capital’s strong performance in 2022 is a testament to David Einhorn’s investment strategy, which focuses on value investing principles. Einhorn’s recent moves on Global Payments (GPN) and Tenet Healthcare (THC) indicate his confidence in their growth prospects. Although analysts have mixed views on THC, GPN has a consensus rating of Moderate Buy and strong fundamentals, making it an attractive investment opportunity.